Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Safety monitoring and information (12)
- Advertising (9)
- Manufacturing (9)
- Scheduling (national classification system) (9)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Clinical trials (3)
- Legislation (3)
- Medicinal cannabis hub (3)
- Import and export (2)
- Breast implant hub (1)
- Committees and advisory bodies (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
185 result(s) found, displaying 151 to 175
-
Corporate reportsAbout compositional guidelines for ingredients permitted for use in listed medicines.
-
Corporate reportsThis guideline is an internationally accepted standard for the designing, conducting, recording and reporting of clinical trials.
-
Corporate reportsSubmissions received on the Proposed regulatory changes related to personalised and 3D printed medical devices have been published
-
Corporate reportsThe TGA has published its Self-Assessment Report for 2016-17
-
-
Corporate reportsReport detailing prescription medicines registrations for 2017
-
Corporate reportsNew generic medicines and biosimilar medicines registered in 2017
-
Corporate reportsA step-by-step guide for prescription medicines
-
Corporate reportsThis document reflects the evidence supporting the use of medicinal cannabis in treating chronic pain and the recommendations of the Chronic Pain Working Group
-
Corporate reportsTGA Stakeholder Survey 2016-17 - questions and answers
-
Corporate reportsSummary of generic and biosimilar prescription medicines registered in Australia in 2016
-
Corporate reportsThe TGA's scientific review on the safety of nanoparticles in sunscreens.
-
Corporate reportsRegulation impact statement: Codeine re-scheduling
-
Corporate reportsEconomic modelling and financial quantification of the regulatory impact of proposed changes to codeine scheduling
-
Corporate reportsRegulation impact statement: General requirements for labels for medicines
-
Corporate reportsThese annual summaries provide details of new prescription medicines registrations and information on new or extended uses for existing medicines.
-
Corporate reportsInfographic - Half Yearly Performance Snapshot - 1 July to 31 December 2015
-
Corporate reportsOTC application placement question and answer tool
-
Corporate reportsReporting medical device adverse incidents
-
Corporate reportsEach year, approximately 40 new prescription medicines containing new active substances are registered.
-
Corporate reportsThe Scheduling Policy Framework (SPF) is a key feature of the revised arrangements for scheduling of medicines and chemicals
-
Corporate reportsThis statement guides decision making to help address concerns with joint replacement prostheses.
-
Corporate reportsTGA approach to disclosure of commercially confidential information (CCI)
-
Corporate reportsFind out when software is classified as an in vitro medical device and how it is regulated.
-